查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591896

人类乳突病毒疫苗市场：按适应症、类型和分销管道划分 - 全球预测 2025-2030

Human Papillomavirus Vaccine Market by Disease Indication (Anal Cancer, Cervical Cancer, Genital Warts), Type (Bivalent, Tetravalent & Nonavalent), Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年人类乳突病毒疫苗市值为43亿美元，预计2024年将达46亿美元，复合年增长率为7.03%，预计2030年将达到69.2亿美元。

人类乳突病毒 (HPV) 疫苗市场的定义是预防与多种癌症（包括子宫颈癌）相关的 HPV 感染。 人类乳突病毒(HPV)疫苗在降低致癌 HPV 株盛行率方面已被证实有效，这推动了对 HPV 疫苗的需求，并在全球公共卫生策略中发挥重要作用。 人类乳突病毒(HPV)疫苗主要用于青春期前儿童和青少年（男性和女性）的免疫计划，以在他们接触病毒之前最大限度地发挥效力。主要最终用途领域包括进行疫苗接种宣传活动的医院、诊所和社区健康组织。主要的成长要素是意识的提高和政府为提高疫苗接种覆盖率所做的努力。导致疫苗配方改进的技术进步也有助于市场扩张。可以扩大对未普及地区的地理推广范围，特别是在发展中国家，由于疫苗取得有限，HPV 相关癌症的发生率很高。此外，对耐热配方的研究可以促进在没有健全的低温运输基础设施的地区的分销。

主要市场统计
基准年[2023] 43亿美元
预测年份 [2024] 46亿美元
预测年份 [2030] 69.2亿美元
复合年增长率（%） 7.03%

然而，由于错误讯息和文化信念而导致的疫苗犹豫等挑战是主要的限制因素。低收入国家的财政限制进一步阻碍了市场成长。寻求创新的公司可以从关注反虚假资讯的教育宣传活动以及投资涵盖更多 HPV 病毒株的广谱疫苗研究中受益。微针贴片等先进的给药方法可透过提高依从性和易于管理来提供创新机会。该市场的特点是官民合作关係潜力巨大。掌握监管变化并与医疗保健提供者和政府形成策略联盟对于这个充满活力和影响力的市场的成长至关重要。

市场动态：快速发展的人类乳突病毒疫苗市场的关键市场洞察

人类乳突病毒疫苗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 人类乳突病毒疫苗在癌症治疗的应用
    • 广受讚誉为突破性的医药创新
    • 政府资助癌症研究和开发
  • 市场限制因素
    • 基础设施不足
  • 市场机会
    • 全球医学界越来越支持引进 HPV
    • 人类乳突病毒(HPV)疫苗生产製程的进展
  • 市场挑战
    • 缺乏社区参与来提高对 HPV 诊断和治疗的认识

波特五力：驾驭人类乳突病毒疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解人类乳突病毒疫苗市场的外部影响

外部宏观环境因素在塑造人类乳突病毒疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解人类乳突病毒疫苗市场的竞争状况

对人类乳突病毒疫苗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵人类乳突病毒疫苗市场供应商的绩效评估

FPNV 定位矩阵是评估人类乳突病毒疫苗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了人类乳突病毒疫苗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对人类乳突病毒疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 人类乳突病毒疫苗在癌症治疗的应用
      • 广泛被誉为突破性的医药创新
      • 政府资助癌症研究和开发
    • 抑制因素
      • 基础设施供应不足
    • 机会
      • 全球医学界越来越支持引进 HPV
      • 人类乳突病毒(HPV)疫苗生产製程的进步
    • 任务
      • 缺乏社区参与来提高对 HPV 诊断和治疗的认识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章人类乳突病毒疫苗市场：依疾病适应症

  • 肛门癌
  • 子宫颈癌
  • 尖圭湿疣
  • 口咽癌
  • 阴茎癌
  • 阴道癌
  • 外阴癌

第七章人类乳突病毒疫苗市场：依类型

  • 二价
  • 四价和九价

第八章人类乳突病毒疫苗市场：依通路划分

  • 政府机构
  • 医生
  • 公私联盟
  • 批发商

第九章美洲人类乳突病毒疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太人类乳突病毒疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲人乳头瘤病毒疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Merck Sharp & Dohme Corp.
  • Mitsubishi Tanabe Pharma Corporation
  • Novavax, Inc.
  • Pfizer Inc.
  • Wantai BioPharm
  • Xenetic Bioscience Inc.
Product Code: MRR-436B79517C6E

The Human Papillomavirus Vaccine Market was valued at USD 4.30 billion in 2023, expected to reach USD 4.60 billion in 2024, and is projected to grow at a CAGR of 7.03%, to USD 6.92 billion by 2030.

The Human Papillomavirus (HPV) vaccine market is defined by its scope in preventing HPV infections, which are linked to several types of cancers, including cervical cancer. The necessity for the HPV vaccine stems from its proven effectiveness in reducing the prevalence of cancer-causing HPV strains, thus playing a crucial role in public health strategies globally. Its application is predominantly in immunization programs targeting preadolescents and adolescents, both female and male, to maximize efficacy before exposure to the virus. Key end-use segments include hospitals, clinics, and community health organizations deploying vaccination campaigns. A primary growth driver is the increasing awareness and government initiatives promoting widespread vaccination. Technological advancements leading to improved vaccine formulations also contribute to market expansion. There is a potential opportunity in expanding geographical outreach to underpenetrated regions, particularly in developing countries where HPV-related cancer rates are higher due to limited access to vaccines. Additionally, research into thermostable formulations can facilitate distribution in areas lacking robust cold chain infrastructure.

KEY MARKET STATISTICS
Base Year [2023] USD 4.30 billion
Estimated Year [2024] USD 4.60 billion
Forecast Year [2030] USD 6.92 billion
CAGR (%) 7.03%

However, challenges such as vaccine hesitancy, driven by misinformation and cultural beliefs, pose significant limitations. Financial constraints in low-income countries further impede market growth. For businesses seeking innovation, focusing on educational campaigns to combat misinformation and investing in research for broad-spectrum vaccines that cover more HPV strains could prove advantageous. Advanced delivery methods, like microneedle patches, offer innovation opportunities by improving compliance and ease of administration. The market is characterized by a high potential for public-private partnerships, as collaborations can boost vaccine access and acceptance. Staying abreast of regulatory changes and forming strategic alliances with healthcare providers and governments will be critical for growth in this dynamic and highly impactful market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Papillomavirus Vaccine Market

The Human Papillomavirus Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Human papillomavirus vaccines associated uses for treatment of cancer
    • Widely commended as a sweeping pharmaceutical innovation
    • Funding by the government for R&D of cancer
  • Market Restraints
    • Inadequate delivery of infrastructure
  • Market Opportunities
    • Growing support for HPV introduction among the global health community
    • Advancements in manufacturing process of HPV vaccines
  • Market Challenges
    • Lack of community engagement to generate awareness regarding diagnosis and treatment of HPV

Porter's Five Forces: A Strategic Tool for Navigating the Human Papillomavirus Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Papillomavirus Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Papillomavirus Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Papillomavirus Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Papillomavirus Vaccine Market

A detailed market share analysis in the Human Papillomavirus Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Papillomavirus Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Papillomavirus Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Papillomavirus Vaccine Market

A strategic analysis of the Human Papillomavirus Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Papillomavirus Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bavarian Nordic A/S, GlaxoSmithKline PLC, Inovio Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novavax, Inc., Pfizer Inc., Wantai BioPharm, and Xenetic Bioscience Inc..

Market Segmentation & Coverage

This research report categorizes the Human Papillomavirus Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Indication, market is studied across Anal Cancer, Cervical Cancer, Genital Warts, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer, and Vulvar Cancer.
  • Based on Type, market is studied across Bivalent and Tetravalent & Nonavalent.
  • Based on Distribution Channel, market is studied across Government Entities, Physicians, Public & Private Alliances, and Wholesalers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Human papillomavirus vaccines associated uses for treatment of cancer
      • 5.1.1.2. Widely commended as a sweeping pharmaceutical innovation
      • 5.1.1.3. Funding by the government for R&D of cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Inadequate delivery of infrastructure
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing support for HPV introduction among the global health community
      • 5.1.3.2. Advancements in manufacturing process of HPV vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of community engagement to generate awareness regarding diagnosis and treatment of HPV
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Papillomavirus Vaccine Market, by Disease Indication

  • 6.1. Introduction
  • 6.2. Anal Cancer
  • 6.3. Cervical Cancer
  • 6.4. Genital Warts
  • 6.5. Oropharyngeal Cancer
  • 6.6. Penile Cancer
  • 6.7. Vaginal Cancer
  • 6.8. Vulvar Cancer

7. Human Papillomavirus Vaccine Market, by Type

  • 7.1. Introduction
  • 7.2. Bivalent
  • 7.3. Tetravalent & Nonavalent

8. Human Papillomavirus Vaccine Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Government Entities
  • 8.3. Physicians
  • 8.4. Public & Private Alliances
  • 8.5. Wholesalers

9. Americas Human Papillomavirus Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Papillomavirus Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Papillomavirus Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bavarian Nordic A/S
  • 3. GlaxoSmithKline PLC
  • 4. Inovio Pharmaceuticals Inc.
  • 5. Johnson & Johnson Services, Inc.
  • 6. Merck Sharp & Dohme Corp.
  • 7. Mitsubishi Tanabe Pharma Corporation
  • 8. Novavax, Inc.
  • 9. Pfizer Inc.
  • 10. Wantai BioPharm
  • 11. Xenetic Bioscience Inc.

LIST OF FIGURES

  • FIGURE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TETRAVALENT & NONAVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC & PRIVATE ALLIANCES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 151. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2023